WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001002586) HUMAN ALPHA 1,2-MANNOSIDASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/002586    International Application No.:    PCT/CA2000/000775
Publication Date: 11.01.2001 International Filing Date: 28.06.2000
Chapter 2 Demand Filed:    12.12.2000    
IPC:
C12N 9/24 (2006.01), C12P 21/00 (2006.01)
Applicants: MCGILL UNIVERSITY [CA/CA]; 845 Sherbrooke West, Montréal, Québec H3A 2T5 (CA) (For All Designated States Except US).
HERSCOVICS, Annette, A. [CA/CA]; (CA) (For US Only).
TREMBLAY, Linda, O. [CA/CA]; (CA) (For US Only)
Inventors: HERSCOVICS, Annette, A.; (CA).
TREMBLAY, Linda, O.; (CA)
Agent: COTE, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA)
Priority Data:
60/140,992 29.06.1999 US
Title (EN) HUMAN ALPHA 1,2-MANNOSIDASE
(FR) ALPHA 1,2-MANNOSIDASE HUMAINE
Abstract: front page image
(EN)The present invention also relates to the use of the recombinant $g(a)1,2-mannosidase for the development of specific agonist or antagonist of the specific $g(a)1,2-mannosidase enzyme for specifically converting Man9GlcNAc to Man8GlcNAc isomer B in degradation mechanism of misfolded proteins, wherein the enzyme has the characteristics of an enzyme encoded by a cDNA sequence set forth in Fig. 1. The present invention also relates to an agonist or antagonist of the $g(a)1,2-mannosidase enzyme of claim 1 for activating or inhibiting the enzyme. The present invention also relates to a method for the treatment of genetic diseases resulting in misfolding of glycoproteins in a patient, which comprises administering an antagonist of $g(a)1,2-mannosidase enzyme of claim 1 for transiently inhibiting the enzyme, thereby stabilizing misfolded glycoproteins and preventing their degradation.
(FR)L'invention porte sur l'utilisation de l'enzyme $g(a)1,2-mannosidase de recombinaison en vue de l'élaboration d'agonistes ou d'antagonistes de la $g(a)1,2-mannosidase servant spécifiquement à la conversion du Man9GlcNAc en isomère B du Man8GlcNAc dans un processus de dégradation de protéines mal pliées, ladite enzyme ayant les caractéristiques d'une enzyme codée par la séquence d'ADNc de la figure 1. L'invention porte également sur un agoniste ou un antagoniste de l'enzyme $g(a)1,2-mannosidase de la revendication 1 assurant respectivement son activation ou son inhibition. L'invention porte en outre sur un procédé de traitement de maladies génétiques provenant d'un mauvais pliage des glycoprotéines chez un patient consistant à lui administrer un antagoniste de l'enzyme $g(a)1,2-mannosidase de la revendication 1 en vue de son inhibition transitoire qui stabilise les glycoprotéines mal pliées et en empêche la dégradation.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)